Microchipped and marked - PART 2
'SOME' PARTNERS IN CRIME
http://web.archive.org/web/20171006114750/http://www.proteus.com/company/partners
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets.
Andrew Thompson
Co-Founder, CEO
Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health. His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket.
Andrew serves on
the World Economic Forum Technology Pioneers
selection committee and he is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform. Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies.
He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.
George Savage, M.D.
Co-Founder, Chief Medical Officer
George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.
George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.
George holds a B.S. in biomedical engineering from Boston University, an M.D. from Tufts University School of Medicine, and an M.B.A. from Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California.
George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley.
Mark Zdeblick, Ph.D.
Co-Founder, Chief Technologist
Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of
Redwood Microsystems.
Mark holds a B.S. in civil engineering and a B.A. in architecture, both from the University of Illinois, and an M.S. in aeronautics and astronautics and Ph.D. in electrical engineering from Stanford University.
Uneek Mehra
Chief Financial Officer
As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting. He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank. At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business.
Uneek has a MBA in strategy and leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.
Molly O'Neill
Chief Commercial Officer
Molly O’Neill is chief commercial officer of Proteus Digital Health, where she leads partnerships with major health systems, payers and key provider customers. Molly is a healthcare industry veteran with a 30+ year track record of developing and executing growth strategies to increase market share and revenues. Prior to joining Proteus, she was the Senior Vice President of business development at Tenet Healthcare, a diversified healthcare services company. Molly has also held leadership roles at Duke Medicine, Partners Healthcare, Inova Health System, Ascension Health Care Network, a joint venture between Ascension Health Alliance and Oak Hill Capital Partners.
Having worked across major provider and healthcare service companies, Molly believes the greatest potential of Digital Medicines is in transforming a patient’s engagement with their physicians, their families and most importantly their own health. Molly is a member of the board of World Care International Inc. and holds degrees from the Medical College of Virginia and Virginia Commonwealth University.
David O'Reilly
Chief Platform Officer
David O’Reilly is chief platform officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to health care and biotechnology companies at L.E.K. Consulting.
David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.
Sean Handel
Senior Vice President Product
Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.
Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.
Neela Paykel
Head of Legal Affairs and Compliance
Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues. Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield.
Neela is a graduate of Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University.
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets
Jonathan Symonds, CBE
Chairman
Jon Symonds, CBE, is
Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England.
Formerly, Symonds was
Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc.
Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman.
Shumeet Banerji, Ph.D.
Board Member
Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.
Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. and Innocoll, AG.
Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.
Regina Benjamin, MD, MBA
Board Member
Dr. Regina Benjamin is the Founder and CEO of BayouClinic in Bayou La Batre, Alabama, and the NOLA.com/Times Picayune Endowed Chair of Public Health Sciences at Xavier University of Louisiana.
She was the 18th United States Surgeon General (2009 – 2013).
Dr. Benjamin serves on the boards of
Kaiser Foundation Health Plan and Hospitals, the largest U.S. health managed care organization, and of Ascension, the world’s largest faith-based health system.
Robert Epstein, M.D., M.S.
Board Member
Dr. Robert Epstein was most recently president of the
Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.
Dr. Epstein is the former
president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association.
He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.
Frank Fischer
Board Member
Frank Fischer has more than 25 years of senior management experience in the medical device industry.
The
president and CEO of the biomedical device company NeuroPace,
he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.
Frank continues to serve on the boards of several privately held medical device companies.
Alan J. Levy, Ph.D.
Board Member
Alan Levy is a venture partner with Frazier Healthcare Ventures and has over 30 years of
senior management experience in the medical device industry.
He serves on the board of Intuitive Surgical, a publicly held company, and several other privately held medical device firms.
Myrtle Potter
Board Member
Myrtle is CEO of Myrtle Potter and Company. A best-selling author, Myrtle has dedicated three decades to serving the healthcare needs of millions of consumers.
She serves on the board of
Everyday Health, Liberty Mutual and is on the board of Trustees of the University of Chicago.
Myrtle was
president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.
Ryan Schwarz
Board Member
Ryan Schwarz is a managing director at The Carlyle Group where he leads the healthcare investing practice for the company’s U.S. Venture & Growth Capital Group,
specializing in medical devices, medical technology and healthcare information technology.
Ryan serves on the boards of AcuFocus, Lipsonix, NeoVista, Cellutions and PixelOptics.
Charles Songhurst
Board Member
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.
Previously, Charles ran corporate strategy for Microsoft and focused on partnering and M&A.
Immanuel Thangaraj
Board Member
Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.
With over 15 years of experience in operations and venture capital, he currently serves on the boards of CBR Systems, Acura Pharmaceuticals, Clear Vascular, Medlogics, and Sound ID.
Our People
Our Purpose
Our Culture
Work for a leader
that's transforming the industry.
We are Proteus Digital Health, the driving force behind an entirely new category of therapy called Digital Medicine. Every day, our employees are blazing new trails at the intersection of pharmaceuticals, technology, software and healthcare. Our company is on the forefront of transformative change to the healthcare industry. We are searching for pioneers, problem-solvers and inquisitive minds to help realize our vision: to improve healthcare for everyone, everywhere. Do you want to work in a dynamic environment where you can grow personally as well as professionally? Then apply today to join the Proteus team.
Make a
difference
in the world
"We are developing a product that is changing people's lives."
Laura Williams, Product Manager.
At Proteus Digital Health, we are developing leading-edge technology that will revolutionize how healthcare is delivered. What does that mean for our associates? They are playing an active role in the evolution of modern healthcare. Whether you are a software engineer, a data analyst or a pharmaceutical expert, you can help develop and deliver solutions that enhance the quality of care for everyone:
Patients get back on track
Physicians get deeper insight into patient health
Healthcare systems can better measure, manage and improve the health of entire patient populations
Euthanizing Our Global System of Sick Care
Time: March 14, 12:30p.m. – 1:30p.m.
Location: Austin Convention Center, Room 8ABC
Speakers: Andy Thompson, CEO with Dr. Leslie Saxon, USC Center for Body Computing
In an era of exploding population growth, chronic illness and new pandemics, our healthcare systems cannot scale, and demands outstrip global resources. But, are we facing a global healthcare crisis or is this an age of unprecedented health-care opportunity? Find out why our current systems of ‘sick care’ fail us and how digital can help scale healthcare for the future. Discover how a human-centered redesign to our healthcare systems can drive new, proactive models of care that mesh better with people’s lives, support physicians and caregivers, reward positive behavior, improve health outcomes and protect human dignity, privacy and security. Part of the IEEE Tech for Humanity Series.
http://web.archive.org/web/20171011010811/http://schedule.sxsw.com/2017/events/PP63029
In an era of exploding population growth, chronic illness and new pandemics, our healthcare systems cannot scale, and demands outstrip global resources. But, are we facing a global healthcare crisis or is this an age of unprecedented health-care opportunity? Find out why our current systems of ‘sick care’ fail us and how digital can help scale healthcare for the future. Discover how a human-centered redesign to our healthcare systems can drive new, proactive models of care that mesh better with people's lives, support physicians and caregivers, reward positive behavior, improve health outcomes and protect human dignity, privacy and security. Part of the IEEE Tech for Humanity Series.
4 December, 2008
Proteus Biomedical Honored by World Economic Forum
Technology Pioneer Award Recognizes Potential of Intelligent Medicine to Improve Business and Society
Redwood City, Calif. – Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has been selected a 2009 Technology Pioneer by the World Economic Forum.
The Technology Pioneer Award honors 34 visionary companies from around the world that a panel of 44 global technology experts believes will have a deep impact on business and society.
To be selected, a company must be involved in the development of life-changing technology innovation, demonstrate visionary leadership, and show signs of being a long-standing market leader. This year is the 10th anniversary of the program, with 320 applications from companies in 15 countries.
“Proteus has developed a unique approach to personalizing therapy,” said Andrew Thompson, Proteus CEO and co-founder.
“We embed micro-sensors into existing drugs and devices, which transmit information, securely, to a person’s cell phone via the Internet.
A person can understand how their body is responding to their therapy, and, if they choose, share this information with a family member, physician or friend to help them stay healthy. We are delighted that the World Economic Forum has recognized the immense potential of this approach and look forward to actively participating in their programs.”
“We congratulate Proteus Biomedical for their remarkable achievements and welcome them to the wider community of the World Economic Forum. During these difficult times, we are certain that the technologies driven by these visionary companies will contribute to the next wave of growth, with the innovative and entrepreneurial spirit that characterizes them,” said André Schneider, Managing Director and Chief Operating Officer of the World Economic Forum.
As a 2009 Technology Pioneer, Proteus Biomedical has been invited to participate in the World Economic Forum’s Annual Meeting in Davos-Klosters, Switzerland, Jan. 28 through Feb. 1, 2009 and the Annual Meeting of the New Champions in Dalian, China, Sept. 10 – 12. These two events bring together the world’s foremost thought leaders in business and government.
The World Economic Forum is an independent, international organization committed to improving the state of the world by engaging leaders in partnerships to shape global, regional and industry agendas. It is incorporated as a Swiss not-for-profit foundation, and has no ties to political, partisan or national interests. The Forum’s motto, “entrepreneurship in the global public interest”, reflects its belief that economic progress without social development is not sustainable, while social development without economic progress is not feasible.
2 July, 2015
First Medical Device Cleared by FDA With Adherence Claim
REDWOOD SHORES, CALIF.
Proteus Digital Health, Inc. today announced that the FDA has expanded the Indications for Use statement for the latest generation of its Ingestible Sensor technology, enabling the device to be used as an aid in the measurement of medication adherence. To the Company’s knowledge, this is the only device with an FDA-sanctioned claim for measuring medication adherence.
An estimated 50% of us do not take our medicines as prescribed, potentially limiting the therapeutic effectiveness of our medicine and resulting in $100-300 billion in avoidable healthcare costs in the US alone due to unnecessary escalation of treatment. There have been many efforts to address this challenge but no products have previously been cleared by the FDA for aiding in the measurement of adherence until now.
“We are delighted that our collaborative work with the FDA continues to enable positive progress,” said Proteus Co-Founder and Chief Medical Officer Dr. George Savage. “We believe that ingestible devices have the potential to speed clinical trials and improve the real-world effectiveness of medicines in community settings.”
When used with a medication, the Proteus Ingestible Sensor marks actual intake time, a quantifiable event that has allowed regulators to grant the expanded indication to the company.
The Ingestible Sensor was approved by the FDA in 2012 and communicates with an adhesive patch, worn on the torso.
The Proteus Patch records time of ingestion along with steps, rest and heart rate, and communicates to a mobile app via Bluetooth.
(!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)
As many players enter the wearables space, Proteus Digital Health is leading a new ingestible category in order to derive unprecedented insights about medication-taking behavior and physiologic response to therapy. Proteus is the only company that combines ingestible, wearable, mobile and cloud computing.
About Proteus Digital Health®
Proteus is creating a new category of therapy: Digital Medicines. Digital Medicine therapy includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicines is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.
Proteus received FDA market clearance in the United States and a CE mark in Europe for its wearable and Ingestible Sensor devices. Headquartered in Redwood City, Calif., Proteus is privately held and funded by leading institutional and corporate investors, including:, Novartis, Otsuka, Oracle and Kaiser Permanente. For more information, visit www.proteus.com.
Proteus Discover helps patients get better, faster — by providing easy access to important data around their medication-taking and health patterns, such as activity, rest and heart rate. With information in hand, patients are able to make more informed healthcare decisions and become more engaged with their overall health.
Once activated by the patient, Proteus Discover:
Provides visibility into medication-taking patterns
Increases connectivity to the patient’s care team
Allows for more relevant conversations with healthcare providers
Makes doctor visits more productive
LET ME COMMENT ON THIS: "Putting patients in control of their health"?
- NO, YOU DID NOT OBTAIN THE PATIENTS' CONSENT TO IMPLANT THESE MICROCHIPS
- YOU DID NOT INFORM THEM THAT YOU WERE DOING SO, THAT YOU WERE IMPLANTING THEM OR INSTILLING THEM WITH THESE MICROCHIPS
- NOR DID YOU GIVE THEM A CHANCE TO TREAT THE RESULTING ADVERSE EFFECTS OR PREVENT DEATH
- YOU ARE HIDING THE FACT THAT THESE MICROCHIPS ARE BEING USED AT ALL
- YOU ARE MAKING FOOLS (CONSPIRACY ANTI VAXXERS) OF PEOPLE WHO SHOW OTHERS THAT THEY HAVE AN IP ADDRESS VIA THEIR BLUETOOTH
AND YOU PLAN TO CENSOR US AND SHUT OUR MOUTHS?
WHAT HAPPENED TO YOUR WEBSITE?
When the E. U. chipped all commercial domestic livestock to ensure quotas were kept by satellite survey, I ranted we were next. My logic was ridiculed as ludicrous. Then came the convenience of personal pets chipped and later, well here we are. Oh, how times change, if you watch closely. Today's plots are tomorrow's conspiracy theory...
In Greek mythology, Proteus (/ˈproʊtiəs, -tjuːs/; Ancient Greek: Πρωτεύς, Prōteus) is an early prophetic sea god or god of rivers and oceanic bodies of water, one of several deities whom Homer calls the "Old Man of the Sea" (hálios gérôn). Some who ascribe a specific domain to Proteus call him the god of "elusive sea change", which suggests the constantly changing nature of the sea or the liquid quality of water.